Atopic dermatitis, also known as eczema, is a common inflammatory skin condition that is characterized by dry, pruritic skin with a chronic relapsing course. Patients with atopic dermatitis may have to endure the social stigma of having a visible skin condition as well as intense itching that can lead to skin trauma and significant sleep disturbances, thereby adversely affecting quality of life. Researchers continue to study the safety and efficacy of novel agents for the treatment of atopic dermatitis, as well as patient- and disease-related factors that can affect patient outcomes.
Many types of biologics have been approved by the US Food and Drug Administration, including monoclonal antibodies (eg, adalimumab [Humira]), therapeutic proteins (eg, filgrastim [Neupogen]), and vaccines (eg, agents used for tetanus and influenza). In 2018, sales of biologics totaled approximately $125 billion, reflecting an increase of 50% from 2014 figures.1 Biologics coordinators play a central role in overcoming challenges to patient access to these agents by navigating benefits, communicating with insurance companies, and advocating for individual patients.
In an interview with Dermatology Practice Management (DPM), Bruce H. Thiers, MD, FAAD, President, American Academy of Dermatology (AAD), explains how the AAD, together with its sister organization, the American Academy of Dermatology Association (AADA), are working closely with federal, state, and local organizations to overcome access to care barriers for patients with dermatologic conditions.
Read Now
